The 2022 Tandem Meetings | TCT highlights: long-term outcomes of beti-cel gene therapy for β-thalassemia
Agnieszka Czechowicz
• 25 Apr 2022
Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, shares her highlights from a session on immune and gene therapy from the TCT meeting. Dr Czechowicz mentions the encouraging long-term results of betibeglogene autotemcel (beti-cel) gene therapy for patients with β-thalassemia showing improved outcomes with transfusion independence and low toxicity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
